23 December 2022 (Friday) - Transfusion News Update

The nice people at Transfusion News sent their update today.

Using Beriplex (and the like) to reduce red cell usage during surgery is an interesting idea.

FDA guidance to reduce malarial transmission is… I don’t know but I suspect a little way behind NHSBT (am I wrong here?)

But I can’t help but the engineering of autologous platelets is never going to catch on.

 

Prothrombin Complex Concentrate Reduces RBC Transfusions during Cardiac Surgery

December 21, 2022 Over one million people undergo complex cardiac surgeries worldwide each year. Cardiac surgeries carry a considerable risk of postoperative bleeding and coagulation complications. During complex cardiac surgeries, fibrinogen levels and coagulation factor activities all decrease by about 40%. [Read More]

FROM OUR SPONSOR Connecting our immunohematology community with transfusion science experts

Is your lab experiencing: Time and resource constraints? Complex cases? Difficulty staying up to date on new challenges? Watch our educational webinars on various immunohematology topics and take the opportunity to hear from experts in the transfusion science field. Ask your transfusion science questions and get answers. [Learn More about Transfusion Science Webinars] Free access upon registration Join from anywhere at anytime Access to on-demand webinars Earn Continuing Education Units Get answers from experts

Updated FDA Guidance to Reduce the Risk of Transfusion-Transmitted Malaria

December 13, 2022 In April 2020, the U.S. Food and Drug Administration (FDA) issued four blood donor eligibility guidelines—including one for malaria—to help alleviate blood shortages during the COVID-19 pandemic. In December 2022, the FDA issued new guidance to reduce the risk of transfusion-transmitted malaria, which is unchanged from the April 2020 guidance. [Read More]

First Autologous Human Transfusion of Engineered Platelets

December 7, 2022 Approximately 2 million units of platelets are transfused each year in the United States, but there are many drawbacks and safety concerns with donor-derived platelets, including bacterial contamination and a short shelf life. In addition, 5% to 15% of patients develop alloimmune platelet transfusion refractoriness (allo-PTR) to human platelet antigens, such as HLA antibodies. [Read More]